 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 4 | 6 | | 2000 | 1 | 0 | 1 | | 2002 | 2 | 3 | 5 | | 2003 | 4 | 3 | 7 | | 2004 | 1 | 2 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 7 | 5 | 12 | | 2007 | 1 | 4 | 5 | | 2008 | 11 | 1 | 12 | | 2009 | 5 | 3 | 8 | | 2010 | 5 | 6 | 11 | | 2011 | 3 | 4 | 7 | | 2012 | 7 | 2 | 9 | | 2013 | 8 | 5 | 13 | | 2014 | 9 | 4 | 13 | | 2015 | 11 | 7 | 18 | | 2016 | 10 | 8 | 18 | | 2017 | 15 | 9 | 24 | | 2018 | 15 | 17 | 32 | | 2019 | 25 | 13 | 38 | | 2020 | 22 | 23 | 45 | | 2021 | 25 | 25 | 50 | | 2022 | 6 | 29 | 35 | | 2023 | 3 | 28 | 31 | | 2024 | 12 | 18 | 30 | | 2025 | 17 | 14 | 31 | | 2026 | 15 | 5 | 20 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Florez N, Patel SP, Salgia R, Sands J, Schenk EL, Shum E, Aldea M, Bestvina CM, Donington J, Garcia CA, Nieva J, Gandara DR, Halmos B, Hirsch FR, Le X, Lee P, Malhotra J, Patil T, Peters S, Riess JW, Rotow J, Rous FA, Sabari J, Sen T, Singhi EK, Velázquez AI, Wakelee HA, Kim ES. Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025. Cancer. 2026 Oct 01; 132(19):e70633.
-
Grattoni A, Paci MM, Arnold N, Aryal S, Artzi N, Bao G, Barcena AJR, Bentov-Arava E, Blanco E, Chua CYX, Corradetti B, Cryer AM, Decuzzi P, De Giorgi M, Fell C, Gao W, Govindaswamy B, Jiang W, Kara G, King MR, Krishnan S, Lagor WR, Lammers T, Larsen J, Manfredi F, Manickam DS, Margulis K, Melancon MP, Meeuwissen S, Miller MA, Mitchell MJ, Mitragotri S, Mojiri A, Cooke JP, Palanki R, Phukan I, Sun X, Stayton PS, Tanifum EA, Veiseh O, Villapol S, Wang J, Williams R, Arancibia RY, Zhang L, Kabanov A, Godin B. Nanomedicine beyond carriers - devices, cells & living therapeutics. Biomed Microdevices. 2026 Sep 08; 28(3).
-
Gurrea-Rubio M, Sloan S, Chada A, Amarista CI, Maeda K, Campbell PL, Tsou PS, Cooney LA, Wicha MS, Fox DA. CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer. Biomolecules. 2026 Aug 17; 16(8).
-
Fox DA, Gurrea-Rubio M. Immunotherapy of cancer without induction of autoimmunity - CD6 as a therapeutic target. Front Immunol. 2026; 17:1845422.
-
Hofmeister E, Major A. Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era. Curr Hematol Malig Rep. 2026 Aug 07; 21(1).
-
Jacobsen LM, Cuthbertson D, Felton J, Sherr JL, Simmons KM, Hosford J, Ismail HM, Greenbaum CJ, Wherrett DK, Pinckney A, Sanda S, DiMeglio LA, Higdon LE, Evans-Molina C. Extended Follow-up of Type 1 Diabetes Immunotherapy Trial Participants Suggests Benign Side Effect Profile. Diabetes Care. 2026 Aug 01; 49(8):1428-1433.
-
Srinivasan S, Eraghi MM, Odiase P, Mazumder S, Ahuja A, Ranganathan S, Patel P, O'Leary S, Guirguis M, Barrie U, Sun MZ, Patel A. Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis. J Clin Neurosci. 2026 Oct; 152:112202.
-
Padilla MS, Li JJ, Zhang Q, Patwari K, Shi S, Yamagata HM, Joseph RA, Hymms BN, Teerdhala SV, Fitzgerald E, Chalom OZ, Gupta K, Alameh MG, Weissman D, Le AD, Mitchell MJ. Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Adv Mater. 2026 Aug; 38(47):e73721.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Fukuda R, Fujiwara Y, Maruyama T, Komohara Y. CD169-positive macrophages in lymph nodes and the tumor microenvironment: harnessing their biology for clinical diagnosis and anticancer therapeutic strategies. Front Immunol. 2026; 17:1852700.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|